STI 2798
Alternative Names: STI-2798Latest Information Update: 08 Jul 2021
At a glance
- Originator Sorrento Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 08 Jul 2021 STI 2798 is available for licensing as of 31 Dec 2020. https://sorrentotherapeutics.com/
- 31 Dec 2020 Preclinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral)
- 31 Dec 2020 Sorrento therapeutics files an IND application for Multiple myeloma before December 2020